Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review

Multiple Myeloma (MM) is characterized by monoclonal proliferation of plasma cells in the bone marrow. Based on cytogenetics, disease can be classified as high risk: t(14;16), t(14;20), and/or del (17p13), intermediate risk: t(4;14) and/or (1q) gain, and standard risk: trisomies, t(11;14) and/or t(6;14) (Strite et al., 2015). Consensus based treatment guidelines recommend 4 cycles of induction therapy such as bortezomib, lenalidomide and dexamethasone (VRd) followed by autologous stem cell transplantation therapy (ASCT) in transplant eligible patients with newly diagnosed multiple myeloma (NDMM) (Strite et al., 2015).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research